GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Current Accrued Expense
Switch to:

Biogen (BUE:BIIB) Current Accrued Expense

: ARS415,053 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's Current Accrued Expense for the quarter that ended in Mar. 2023 was ARS415,053 Mil.

Biogen's quarterly Current Accrued Expense declined from Sep. 2022 (ARS415,794 Mil) to Dec. 2022 (ARS356,390 Mil) but then increased from Dec. 2022 (ARS356,390 Mil) to Mar. 2023 (ARS415,053 Mil).

Biogen's annual Current Accrued Expense increased from Dec. 2020 (ARS214,029 Mil) to Dec. 2021 (ARS221,178 Mil) and increased from Dec. 2021 (ARS221,178 Mil) to Dec. 2022 (ARS356,390 Mil).


Biogen Current Accrued Expense Historical Data

The historical data trend for Biogen's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Accrued Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95,782.02 146,445.32 214,029.39 221,178.20 356,390.36

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Current Accrued Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 217,374.73 363,035.62 415,793.97 356,390.36 415,052.56

Biogen Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Biogen Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Biogen's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines